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Abstract
Background: The Her2 receptor is overexpressed in up to 25 % of breast cancers and is associated with a poor
prognosis. Around half of Her2+ breast cancers also express the estrogen receptor and treatment for such tumours
can involve both endocrine and Her2-targeted therapies. However, despite preclinical data supporting the effectiveness
of these agents, responses can vary widely in the clinical setting. In light of the increasing evidence pointing to the
interplay between the tumour and its extracellular microenvironment as a significant determinant of therapeutic
sensitivity and response here we investigated the impact of 3D matrix culture of breast cancer cells on their
therapeutic sensitivity.
Methods: A 3D Matrigel-based culture system was established and optimized for the growth of ER+/Her2+ breast
cancer cell models. Growth of cells in response to trastuzumab and endocrine agents in 3D culture versus routine
monolayer culture were assessed using cell counting and Ki67 staining. Endogenous and trastuzumab-modulated
signalling pathway activity in 2D and 3D cultures were assessed using Western blotting.
Results: Breast cancer cells in 3D culture displayed an attenuated response to both endocrine agents and trastuzumab
compared with cells cultured in traditional 2D monolayers. Underlying this phenomenon was an apparent matrix-induced
shift from AKT to MAPK signalling; consequently, suppression of MAPK in 3D cultures restores therapeutic response.
Conclusion: These data suggest that breast cancer cells in 3D culture display a reduced sensitivity to therapeutic agents
which may be mediated by internal MAPK-mediated signalling. Targeting of adaptive pathways that maintain growth in
3D culture may represent an effective strategy to improve therapeutic response clinically.
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Background
Breast cancer is the most frequently diagnosed female
cancer globally and is the leading cause of cancer death
in women [1]. In the UK, the current lifetime risk of
developing the disease for women is currently 1 in 8
[2, 3]. Overexpression or amplification of the Her2
gene product occurs in around 20 % of all breast cancers
and around half of Her2+ tumours will also co-express the
estrogen receptor (ER) [4]. Despite the effectiveness of
endocrine and Her2-targeted therapies for such tumours in
pre-clinical, two-dimensional models, the clinical response
to these treatments can vary greatly with therapeutic resist-
ance a limiting factor; resistant tumours frequently present
as metastases with associated poor prognosis highlighting
the need for more effective treatments in the early phases
of the disease.
Increasing evidence now points to the interplay between
the tumour and its surrounding microenvironment as a
significant determinant of therapeutic sensitivity and re-
sponse [5, 6] with tumour-stroma interactions demon-
strated to influence tissue response to ionizing radiation
[7], chemotherapeutics and more recently targeted agents
[8, 9]. The influence of stroma on the therapeutic re-
sponse to cytotoxic drugs has been investigated through
studies using matrix-rich 3D culture environments where
tumour cells grown in such a manner exhibit resistance to
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doxorubicin compared to responses in traditional 2D cul-
ture [10]. Furthermore, the migration of fibrosarcoma cells
in 2D culture is decreased by doxorubicin chemotherapy
whereas this effect is completely abolished when grown in
the context of a 3D collagen-rich matrix [11].
Tumour cell-extracellular matrix interactions may
attenuate drug response through alterations in internal
signalling pathways, possibly as a result of integrin ac-
tivation. For example, matrix-induced β-1 integrin
activation results in suppression of chemotherapy-induced
apoptosis and enhanced tumourigenecity [12] and pro-
motes resistance to cisplatin [13]. The interaction of cells
with laminin, mediated through a range of alpha and beta
integrins, is also able to enhance tumourigenecity and
decrease sensitivity to cytotoxic agents [14]. Importantly,
clinical studies have shown that ECM composition of
tumour correlates with lack of clinical response to chemo-
therapy and reduced overall survival [15, 16]. Thus a
better understanding of how tumours interact with their
surrounding microenvironment is crucial for the develop-
ment of more effective clinical treatment strategies. Here
we have investigated the impact of the extracellular matrix
on the therapeutic response and signaling pathway activity
of ER+/Her2+ breast cancer cells with a view to identify-
ing potential targets to improve therapeutic response.
Methods
Antibodies/Reagents
Routine cell culture reagents (RPMI 1640 media, Foetal
Calf Serum (FCS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT), Trypsin/EDTA, Amphoter-
icin B (Fungizone), penicillin/streptomycin) were purchased
from Invitrogen (Paisley, UK). Basement membrane matrix
(Matrigel) and BD Cell Recovery Solution (Matrisperse)
were obtained from BD Biosciences (supplied by VWR
International Ltd, UK). The MEK inhibitor, U0126, and
AKT inhibitor, MK-2206 2HCL, were from Promega
Uk and Stratech Scientific Ltd, UK respectively. En-
hanced chemiluminescence Supersignal® Western blot-
ting detection reagents were purchased from Pierce and
Warriner Ltd (Cheshire, UK). Antibodies recognizing
total and phospho forms of Akt, MAPK, Erk1/2 and
erbB2 were from Cell Signaling Technology (MA, USA);
anti-GAPDH, anti-β-actin and secondary HRP-conjugated
antibodies were from Sigma-Aldrich (Poole, Dorset, UK).
The total-ER (clone 6 F11) mouse anti-human primary
antibody was from NovoCastra.
Cell lines and reagents
Two ER+/Her2+ cell models, BT474 and MDAMB361,
were obtained from ATCC (American Type Culture Collec-
tion) and routinely maintained in RPMI supplemented with
10 % FCS, penicillin (100units/ml), streptomycin
(100ug/ml) and amphotericin B (2.5ug/ml). Experiments
utilising endocrine agents were performed in steroid-
depleted culture conditions (phenol red-free RPMI contain-
ing 5 % charcoal-stripped FCS and antibiotics as above).
Measurement of cell growth in 2D cell culture
Cells were harvested using trypsin/EDTA and reseeded
into 48-well plates at a density of 20,000 cells/well in
fresh media containing treatments as indicated. Cells
were allowed to grow for 10 days with medium changes
every 3 days. At the end of the experiment, the medium
was removed and 0.5 ml of trypsin/EDTA was added to
each well. Once the cells were in suspension, cells were
drawn into a 5 ml syringe through a 25G needle three
times to obtain a single-cell suspension. The wells were
then washed with 0.5 ml of fresh Isoton II solution and
this was then drawn up into the syringe. This final wash
was repeated twice to give a total volume of 2 mls in the
syringe. The solution was then added to 8 mls of Isoton
II solution in a counting vial to make up a volume of
10mls. Cells were then counted (three counts per well)
using a Coulter™ Multisizer II.
Three-dimensional (3D) cell culture
For analysis of cellular growth in 3D culture, we used a
modified version of the ‘3D on-top’ assay reported by
Lee et al. [17] optimised for the cell lines under test here
(Additional file 1: Figure S1A). Using this method
allowed for the imaging of cell colonies in a single plane
and cellular retrieval for counting assays. The 3D culture
protocol was performed as follows: The wells of a 48-
well plate were pre-coated in phenol red-free Matrigel
(80ul/well) and incubated at 37 °C for 30 min to allow
gel formation. Cells were harvested using trypsinisation
and pelleted by centrifugation at 115 g before resuspen-
sion in fresh media and seeding into Matrigel-coated at
a final concentration of 0.20 × 105 cells/cm2. The cells
were allowed to settle and attach to the Matrigel for
30 min at 37 °C following which they were overlaid with
1.2 mls of fresh media containing 10 % (v/v) Matrigel..
Cell cultures were maintained for up to 10 days, re-
placing the Matrigel-medium mixture every 3 days.
Recovery of cells from 3D culture for experimental
analysis
Cells were recovered from the 3D cultures for counting,
immunocytochemical analysis or Western blotting using
a modification of a previously reported method [18] and
Additional file 2: S1B. Briefly, the medium was removed
and each well was washed 3x with ice cold PBS. 10ul
matrisperse (BD Biosciences) was added to each well
and well contents gently recovered by scraping with a
1 ml syringe plunger. Recovered cells, along with two
further well washings with matrisperse, were collected in
universal tubes and left on ice for 60 min. At this stage,
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the cells extracted from 3D matrix are still in colonies
and could be processed for cellblocks and immunocyto-
chemistry. For cell counting and immunoblotting the
following steps were performed. Universal tubes were
spun at 5000 rpm for 5 min and the supernatant dis-
carded. The cell pellets were re-suspended in 0.5 ml of
trypsin/EDTA and incubated at 37 °C for 5 min prior to
the addition of 1.5 ml of fresh Isoton II solution. This
solution was drawn into a 5 ml syringe through a 25G
needle three times to obtain a single-cell suspension.
The solution was then added to 8 mls of Isoton II solu-
tion in a counting vial to make up a volume of 10mls.
Cells were then counted using a Coulter™ Multisizer II.
At least three counts were taken from each well.
Western blotting
Cells were grown as monolayers or as 3D cultures in
35 mm dishes ± treatments then washed twice with ice-
cold PBS and lysed with Triton-X100 lysis buffer (sodium
orthovandate 2 mM, phenylmethylsulfonyl fluoride 1 mM,
sodium fluoride 25 mM, sodium molybdate 10 mM, pheny-
larsine 20uM, and leupeptin 10ug/ml and aprotinin 8ug/ml
in 50mMTris-HCL, pH8.0 containing 0.1 % TX-100). Cells
were then collected using a cell scraper and transferred to a
1.5 ml micro-centrifuge tube, incubated on ice for 15 min
before centrifugation at 13000 rpm, 15 min, 4 °C. For cells
growing in 3D culture. the matrigel was first depolymerized
using matrisperse prior to addition of lysis buffer. The su-
pernatants were removed and stored at −20 °C until re-
quired. After protein determination (BioRad DC protein
assay kit), equal amounts of protein were incubated with 2x
sample loading buffer (4 % SDS, 10 % 2-mercaptoethanol,
20 % glycerol, 0.004 % bromophenol blue in 0.125 M Tris–
HCl pH 6.8) and heated to 100C for 5 min. Cell lysates,
together with molecular weight standards, were then sepa-
rated on 8 % gels using SDS-PAGE. After transfer onto
nitrocellulose membranes and blocking with 5 % milk (in
TBS), membranes were probed for specific target proteins
using appropriate antibodies.
Preparation of cell pellet blocks for immunostaining
2D and 3D cultures of BT474 and MDAMB361 cultures
were prepared and grown in 35 mm dishes ± treatments
as indicated for 7 days. For standard (2D) cultures the
media was aspirated and the cells gently removed using
a cell scraper and re-suspended in phenol red RPMI. For
3D cultures, cell colonies were dissociated from the
Matrigel™ Matrix using BD cell recovery solution in
order to detach colonies whilst retaining their three-
dimensional integrity.
The cells from 2D and colonies from 3D were then
centrifuged at 1000 rpm for 5 min and fixed immediately
in 4 % formaldehyde/PBS (1 hr room temp). Cells were
then transferred to a Eppendorfs where they were allowed
to settle under gravity for a further 50 min (in 4 % formal-
dehyde/PBS). For each sample, the supernatant was re-
moved and a 1:1 ratio of molten 12 % Noble agar was
added to the cell suspension. This was quickly transferred
by Pasteur pipette into an inverted 2 ml syringe with its tip
cut off, and clamped in a retort stand which functioned as
a mould. The agar was left overnight to set. A cell plug was
extruded from the syringe and cut into 5 mm sections
placed into a standard Histo-TEK® cassette. These were
fixed for a further 2 h in a 4 % formaldehyde/PBS solution.
The pellets were then dehydrated in a series of graded
ethanol solutions (10 to 100 % v/v) for 45 min each
(overnight for 70 %), cleared in Xylene for 2 h, left in a
molten paraffin wax bath for 2 h (under vacuum for
30 min) before being embedded in paraplast medium to
create a block. At least three pellets were assembled into
each block which was subsequently sectioned at 5 μm to
check integrity and density of cells in the pellets using
H&E staining.
Immunocytochemical staining
A 3 % aqueous solution of hydrogen peroxide was added
to the sections for 5 min to block endogenous peroxidases
following which sections were washed in PBS for a further
5 min. Antigen retrieval was performed by pressure-
cooking sections in 2 l, 0.01 M Sodium Citrate Buffer
(pH6) for 2 min. Slides were cooled under running tap
water for 10 min then washed in PBS for 5 min.
For measurement of the total-ER, erbB2 and Ki67,
sections were blocked with 20 % Normal Human Serum
(ER) or 1 % BSA (erbB2) in PBS for 10 min prior to
incubation with primary antibodies (dilutions in PBS
were ER:1/80 and erbB2:1/350) for 1 h. After washing in
PBS, a peroxidase labelled secondary antibody (Dako
Mouse EnVision) was added and sections incubated for
2 h at room temperature. Slides were washed in PBS
before addition DAB (Dako) for 10 min and rinsing in
distilled water. Sections were counterstained with 0.5 %
methyl green, allowed to air dry and then mounted.
For the Ki67 assay, a modified protocol was performed.
Antigen retrieval was performed by microwaving sections
in 1 l Citric Acid Buffer (2.1 g/l, pH 6) for 30 min at 560 W
and cooling slides under running tap water for 10 min. The
primary antibody was applied (Dako MIB (M7240) at 1/50
dilution in 0.1 % BSA/PBS) for 2 h, room temperature.
Washing and secondary antibody incubation was per-
formed as for the ER assay above. Ki67 stained sections
were counterstained using 4 % haematoxylin.
Statistical analysis
Comparisons of treatment effects on cell growth were
performed using a paired t-test. Data from the cell pro-
liferation assays were analyzed using GraphPad Prism
(GraphPad Software Inc., San Diego, CA) to calculate
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the concentration of drug required for 50 % inhibition of
cell growth (GI50) by nonlinear regression curve fitting
with sigmoidal dose response (variable-slope) parameter.
Results
Breast cancer cells growing in 3D culture retain
characteristics of 2D cultures
In this study we set out to investigate the effects of 3D
culture in a matrix-enriched environment on the thera-
peutic sensitivity of two ER+/Her2+ breast cancer cell
models. After establishing an appropriate in vitro 3D
culture system, we first explored whether 3D culture
had any effect on the morphological appearance of the
cell lines. Bright field images of BT474 (Fig. 1a) and
MDAMB361 (Fig. 1b) cells in 2D and 3D culture re-
vealed that cells growing in 3D culture formed tightly
packed spherical aggregates with a rounded (BT474) or
grape-like (MDAMB361) appearance compared to 2D
monolayers growth.
We subsequently wished to explore whether 3D cul-
ture affected expression of cellular receptors that are the
key therapeutic targets in these breast cancer models
namely the Her2 and ER. Immunocytochemical staining
of these markers did not reveal any loss or change in
cellular localization when cells were cultured in 3D com-
pared with 2D (Fig. 1c, d).
We then measured the basal growth of both cell lines
in control medium over a 7-day period in the 3D and
2D contexts using coulter counting (Fig. 2a). Growth
rates of cell lines cultures in 2D and 3D appeared very
similar and, whilst there was a modest reduction in
growth rate in 3D culture, this was not statistically sig-
nificant. Growth data by coulter counting was further
validated by assessing expression of Ki67 (Fig. 2b). Again,
no significant differences were observed between cells
growing in 2D versus 3D culture.
Growth of ER+/Her2+ breast cancer cells in 3D culture
attenuates their response to endocrine agents and
trastuzumab
Studies have suggested that the 3D microenvironment
may contribute to loss of chemosensitivity. To begin to
explore this in the context of ER+/Her2+ breast cancer,
BT474 and MDAMB361 cells were grown in 2D mono-
layers or 3D cultures and exposed to a range of concen-
trations of tamoxifen, fulvestrant or trastuzumab for
7 days after which cell numbers were counted. Whilst
both cell lines exhibited a dose-dependent inhibition of
cell growth in response to these agents in 2D culture
conditions, the effects of endocrine agents and trastuzu-
mab on cell growth was significantly reduced in 3D cul-
ture (Fig. 3a, b). IC50 values for each agent in 2D and
Fig. 1 Breast cancer cells growing in 3D culture retain characteristics of 2D cultures. Bright field images of BT474 (a) and MDAMB361 (b) cells in
2D and 3D culture revealed that cells growing in 3D culture formed tightly packed spherical aggregates with a rounded (BT474) or grape-like
(MDAMB361) appearance compared to 2D monolayers growth. Immunocytochemical staining of cellular receptors namely the Her2 and ER did
not reveal any loss or change in cellular localization when cells were cultured in 3D compared with 2D (c, d)
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3D culture were calculated (Table 1) which again demon-
strated that sensitivity was lost in 3D culture conditions.
Combination treatment of ER+/Her2+ cell lines using
endocrine agent and trastuzumab is attenuated in 3D
culture
To further explore the effects of 3D culture on drug
response, we exposed BT474 or MDA361 cells to
endocrine agent, trastuzumab or both agents in com-
bination for 10 days after which cell counting were
performed using a coulter counter. These experiments
confirmed the dose response studies showing that 3D
growth suppressed the growth-inhibitory effects of
these agents. Moreover, the growth inhibitory effects
of both agents in combination were also attenuated
(Fig. 4a, b).
Analysis of the proliferation marker, Ki67, in cells
cultured in this manner again conformed the loss of
response to these therapeutics in 3D culture, showing a
greater amount of staining in drug-treated, 3D cultured
BT474 and MDA361 cells versus their 2D-cultuerd
counterparts (Fig. 5a, b; Table 2)
Culture of breast cancer cells in 3D promotes AKT to
MAPK pathway switching
Having confirmed the attenuation of growth inhibitory
effects of treatments in 3D versus 2D cultures we next
wished to explore whether this could be explained
through any significant changes in cellular signaling
pathways potentially activated/suppressed in one envir-
onment compared to the other. Cell lysates from both
cell lines grown in 2D and 3D were analyzed using
Western blotting (Fig. 6a, b). These data revealed that
growth in 3D culture resulted in a significant loss of
PI3K/AKT pathway activity and a gain in MAPK signal-
ing in both cell lines.
A B
Fig. 2 Basal growth rate of BT474 and MDAMB361 cells in 3D and 2D cultures. The basal growth of both cell lines (BT474 and MDAMB361) in
control medium over a 7-day period in the 3D and 2D contexts were measured using coulter counting (a). There was a modest reduction in
growth rate in 3D culture which was not statistically significant. Growth data by coulter counting was further validated by assessing expression of
Ki67 (b). Again, no significant differences were observed between cells growing in 2D versus 3D culture
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MAPK pathway activity is further increased in response to
treatment in 3D culture
Given that 3D culture appeared to promote a shift from
AKT to MAPK pathway, we wished to explore whether
endocrine or targeted therapy had any effects on these
pathways in light of the reduced chemosensitivity ob-
served in 3D culture. Western blots and densitometry
analysis (Fig. 7) of 2D and 3D cultured cell samples
following endocrine agents and trastuzumab revealed that
in 2D culture, monotherapy treatments had generally little
effect on AKT (although suppression was observed in
BT474 cells for trastuzumab) whilst combination treat-
ments were effective at suppressing AKT activity in BT474
cells only. In contrast, the gain in MAPK activity observed
in 3D culture generally appeared to be further augmented
in response to single agents and, to a lesser degree, endo-
crine treatment and trastuzumab combined.
Inhibition of MAPK activity in 3D culture restores
sensitivity to endocrine and Her2-targeted agents
To explore whether MAPK signaling played a role in me-
diating therapeutic insensitivity in 3D culture, 3D cultures
of BT474 and MDAMB361 cells were treated for 10 days
with trastuzumab and endocrine treatments as shown ±
MEK inhibitor (U0126) or AKT inhibitor (MK-2206) and
their growth subsequently evaluated. For both cell lines,
inhibition of AKT did not greatly affect their growth or
stimulate apoptosis in 3D when used as single agents nor
did AKT inhibition significantly improve the response
seen with trastuzumab, tamoxifen or fulvestrant (Fig. 8a, b
and Additional file 3: Figure S2). Inhibition of cell growth
was modestly improved when the MEK inhibitor was used
as a single agent although this was unlikely due to cell loss
through apoptosis (Additional file 3: Figure S2). However,
MEK inhibition improved the response to tamoxifen and
fulvestrant (BT474 cells) and trastuzumab (MDA361 cells)
(Fig. 8a,b). These effects corresponded to a further sup-
pression of MAPK in the cell lines (Fig. 8c, d).
Discussion
In this study we have investigated the impact of 3D cul-
ture on breast cancer cell sensitivity to therapeutic agents
Fig. 3 3D culture attenuates response to tamoxifen, fulvestrant and trastuzumab. BT474 (a) and MDAMB361 (b) cells were grown in 2D (SQUARE) or
3D (CIRCLE) cultures in the presence or absence of tamoxifen, fulvestrant or trastuzumab for 7 days after which cell number was assessed by Coulter
counting. For both cell lines, culture in 3D conditions attenuated their response to endocrine agent or trastuzumab. Plots are mean cell growth ± SD
Table 1 IC50 data for tamoxifen, fulvestrant and trastuzumab in
2D versus 3D culture conditions
Mean GI 50 (nM)
Cell line Trastuzumab Tamoxifen Fulvestrant
3D 2D 3D 2D 3D 2D
BT474 13 1.7 >100 14.5 100 9
MDAMB361 >100 >100 88 9 76 8.3
Cell growth data from Fig. 3 were analysed using GraphPad to obtain IC50
values. These were higher for both cell lines for each agent when cultured
in 3D
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Fig. 4 3D culture attenuates the therapeutic response of ER + Her2+ cells. BT474 (a) and MDAMB361 (b) cells were grown for 10 days as 2D
monolayers or as 3D cultures in Matrigel and their proliferative response to trastuzumab and endocrine monotherapy or their combination assessed
using coulter counting. The growth inhibitory effects of trastuzumab and endocrine therapy on day 10, either as single agents or in combination, were
significantly attenuated in 3D vs. 2D cultures. * p < 0.05, ** p < 0.001. t-test. C = control, H = trastuzumab (Herceptin), T = tamoxifen, F = fulvestrant
Fig. 5 Drug-induced loss of Ki67 is suppressed in 3D culture, BT474 and MDAMB361 cells were grown for 10 days as 2D monolayers or as 3D
cultures in Matrigel in the presence of either trastuzumab and endocrine (tamoxifen or fulvestrant) monotherapy or their combination treatments.
CON = control, HER = trastuzumab (Herceptin), TAM = tamoxifen, FAS = fulvestrant. ICC staining of BT474 (a) and MDAMB361 (b) cells for
proliferative antigen Ki67 revealed less suppression of this antigen in 3D vs. 2D culture in response to treatments
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in order to better understand how drug response may be
influenced by the tumour microenvironment. Our find-
ings suggest that, for Her2+/ER+ luminal breast cancer
models, their therapeutic response to the Her2 targeting
agent, trastuzumab, and also to anti-ER therapies (tamoxi-
fen and fulvestrant) is attenuated in 3D matrix enriched
culture compared with 2D monolayer cultures.
2D culture systems are frequently employed to determine
the effectiveness of targeted therapies in vitro although in
vivo responses often fail to mirror this. For example, in
vitro sensitivity to alkylating agents does not necessarily
correlate with in vivo responsiveness [19], an effect that also
holds true to targeted agents such as imatinib, where the
degree of inhibition of proliferation obtained in vivo was
substantially lower than that achieved in vitro with similar
concentrations [20]. Our data and that of others thus
suggest that better modelling of the in vivo environment
should be considered when testing therapeutic agents in
vitro. Whilst the in vivo tumour microenvironment is com-
plex, one element of this with significant impact on thera-
peutic sensitivity appears to be the surrounding
protienatious matrix. Indeed, a number of studies demon-
strate that the tumour-matrix interaction plays an import-
ant role in governing the chemosensitivity of tumours and
may also confer resistance to chemotherapeutic agents
[10–14]. 3D matrix enriched models more closely mimic
the in vivo conditions required for the signaling and behav-
iour of both normal mammary cells and also breast cancer
cells and this has been confirmed by several studies. [21–
24], when compared with 2D models. An in-depth prote-
omic analysis of Matrigel has revealed a complex and intri-
cate mixture of proteins consisting of structural proteins,
growth factors and their binding proteins as well as several
other proteins of roles that are not clear in cell culture [25].
This study suggests that it will be challenging to replace
Matrigel in a variety of cell culture and experimental assays
due to its complexity. By using traditional 2D monolayer
cultures, essential cellular functions that are present in tis-
sues are missed and the use of three-dimensional cultures
bridges this gap between cell culture and live tissue [26].
Our data here point to the importance of using appropriate
in vitro models to identify the therapeutic efficacy of tar-
geted agents in preclinical studies. Although complex
models, which simulate several aspects of the tumour
microenvironment, including three-dimensional culture
systems, have been developed to evaluate the efficacy of
therapeutic agents, these have not been adapted for
routine use in high-throughput pre-clinical screening to
maximize the selection of agents likely to display clin-
ical effectiveness.
Our data points to a role for the ECM as a determinant
of trastuzumab response as do other studies that demon-
strate a lack of response to Her2 targeted agents when
breast cancer cells are grown in 3D, laminin-rich cultures
[27]. One of the underlying mechanisms here may be
ECM-mediated activation of integrin signalling [12, 13]
since targeting the β1 integrin, a critical mediator of lam-
inin binding is able to restore therapeutic sensitivity to
antiHer2 agents in this study. Whilst inhibition of specific
integrins can improve chemotherapy response in 3D cul-
ture models, it does represent a challenge therapeutically
Table 2 Ki67 H-Scores of BT474 and MDA361 cells in 2D versus
3D culture in response to endocrine agents and trastuzumab
A (BT474): Ki67 antigen staining- expressed as % control
C H T F H + T H + F
3D 100 106 70 27 6 6
2D 100 33 62 25 6 2
B (MDAMB361): Ki67 antigen staining- expressed as % control
C H T F H + T H + F
3D 100 75 70 25 25 5
2D 100 9 64 5 9 5
H-Scoring of immunohistochemical staining (Fig. 5) were used to determine the
percent of cells positive for this antigen after drug treatment. Cells cultured in 2D
had less Ki67-positive cells after drug treatment than those cultured in 3D
Fig. 6 growth in 3D promotes loss of PI3K/AKT and gain in MAPK
signaling. Cells were growth in 2D or 3D culture, lysed and proteins
analyzed by Western blotting. 3D culture resulted in a significant
loss of PI3K/AKT pathway activity and a gain in MAPK (BT474) and
MEK (BT474 and MDAMB361 cells)
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Fig. 7 (See legend on next page.)
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as multiple integrin members are expressed, many of
which will be involved in the tumour cells’ interaction
with the diverse protein components of the ECM. Thus
an alternative strategy would be to target points of conver-
gence of signals originating from multiple integrin mem-
bers. Our data suggests that inhibition of MEK signalling,
known to be activated following stimulation of multiple
integrin members [28–30], might represent such an ap-
proach. We show here that inhibition of MEK alone had
an inhibitory effect on 3D cell growth whereas Akt inhib-
ition did not, supporting a role for the MEK pathway in
this process as we observed an increase in MEK activity
when cells were grown in 3D as opposed to 2D culture.
Conversely, Akt activity in 3D was reduced. Other groups
have additionally demonstrated enhanced sensitivity to
MEK inhibitors in 3D culture using models of triple nega-
tive breast cancer [10].
ErbB receptors are able to signal through a number of
pathways including Akt and MAPK to regulate cell pro-
liferation, migration, differentiation and apoptosis. erbB2
itself has been implicated in both activation of Akt and
MAPK/MEK signalling which may reflect its dimerization
state in the cell models under investigation. In our study it
was interesting to note that despite erbB activity in both
BT474 and MDA361 cells, only modest MAPK kinase ac-
tivity was seen in monolayer culture in contrast to Akt.
However, clinical studies have suggested that erbB2 and
MEK signalling are linked via Pak1 (p21-activated kinase)
(See figure on previous page.)
Fig. 7 Endocrine agents and trastuzumab augment MAPK activity in 3D culture. Comparison of signaling pathway activation in 2D versus 3D
culture in response to tamoxifen, fulvestrant and trastuzumab monotherapy and in combination was investigated using Western blotting with
accompanying densitometry of normalized blots. For BT474, trastuzumab and endocrine treatments, either as monotherapies (a) or in combination (b),
suppressed MAPK signaling in 2D monolayers in contrast to 3D culture, where MAPK activity was maintained or augmented. In the case of MDAMB361
cells, treatment with trastuzumab and endocrine agents, either as single agents (c) or in combination (d), resulted in the loss of MAPK signaling in the 2D
context in contrast to 3D culture where MAPK signaling was augmented. C = control, H = trastuzumab (Herceptin), T = tamoxifen, F = fulvestrant
A B
C D
Fig. 8 Targeting MAPK improves therapeutic response in 3D culture. 3D cultures of BT474 (a) and MDAMB361 (b) cells were treated for 10 days
with trastuzumab and endocrine treatments as shown ±MEK inhibitor (U0126) or AKT inhibitor (MK-2206) and cell growth evaluated by coulter
counting. Further samples were analysed for MAPK and AKT activity (c, d) by Western blotting. Inhibition of MEK significantly improved
trastuzumab and endocrine response in MDMB361 and BT474 cells respectively. In both cell types, MEK inhibition but not AKT inhibition resulted
in an augmentation of treatment-induced MAPK activity suppression (c, d; no data is shown for AKT in MDAMB361 cells as AKT activity was not
detectable in cells in 3D culture). AKT inhibition did not improve growth suppression alone or in conjunction with trastuzumab or endocrine
agent. C = control, H = trastuzumab (Herceptin), T = tamoxifen, F = fulvestrant. *p < 0.05 vs. no inhibitor
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[31], a context that involved tumour cell-matrix interac-
tions and is supported by our 3D data. Moreover, the MEK
pathway is required for maintenance of tumour cell dor-
mancy in 3D in vitro cultures and in vivo [32]. Together
these data further implicate MAPK/MEK as a pathway
with relevance in the microenvironmental context.
Our findings further support other studies which sug-
gest that the differential response to therapeutic agents
seen in matrix enriched 3D cultures are a result of distinct
downstream signaling cascade activation by cell-ECM in-
teractions. Culture of both BT474 and MDAMB361 cell
lines in 3D models promoted AKT to MAPK switching
with a further in crease in MAPK activity observed in re-
sponse to treatment with either anti-Her2 or anti-ER
agents. Enhanced MEK activity is reported in in human
breast cancers compared with benign breast tissue [33]
whilst survival analysis has shown a positive correlation
between elevated MAPK activity in primary breast cancers
and decreased relapsed free survival [34]. Moreover, MEK
pathway activity is associated with shortened duration of
anti-hormonal response and decreased patient survival
[35] supporting to our pre-clinical observations. As such,
these data suggest that the MEK pathway may represent a
compensatory mechanism that drives cell growth in the
presence of targeted therapy. Interestingly, we observed
differential sensitivity to endocrine agents between the
two cell models despite them both being a Her2+/ER
+ phenotype. In BT474 cells, which appeared intrinsically
insensitive to endocrine agents, MAPK inhibition along-
side endocrine agent resulted in a significant improvement
in therapeutic response whereas no additional benefit was
seen when the MAPK inhibitor was combined with her-
ceptin. Corresponding changes in MAPK activity seemed
to underlie this since only endocrine agent plus MEKi
were able to further reduce MAPK activity. Moreover,
these data also support others’ which suggest presence of
the Her2 can limit endocrine response through MAPK
signalling and modulation of ER function [36]. In the
microenvironmental context, augmentation of MAPK
activity, likely to occur through multiple mechanisms in-
cluding integrins and erbB receptors, could further attenu-
ate endocrine sensitivity. However the case for
MDAMB361 models is less clear. Whilst also ER+/Her2+,
these cells were intrinsically more sensitive to endocrine
agents than BT474 models despite having lower Her2 activ-
ity in comparison. Intriguingly, treatment of MDAMB361
cells with herceptin resulted in further elevation of MAPK
activity; consequently, and largely in contrast to endocrine
agents, inclusion of the MAPK kinase pathway inhibitor
proved beneficial in terms of inhibition of cell growth.
Thus, our data suggest that MEK inhibition in 3D cul-
ture can partially restore sensitivity to therapeutic agents
and that this may be particularly useful in the context of
de novo endocrine-resistant ER+/Her2+ cancers.
Conclusions
Our data here point to the importance of the tumour
microenvironment as a determinant of therapeutic sensi-
tivity and suggests that inhibitors of MEK signalling may
represent a valuable therapeutic consideration in this
context. The recent development of several MEK inhibi-
tors with potent in vivo anticancer activity have been de-
scribed [37] which may hold potential for future clinical
application.
Additional files
Additional file 1: Figure S1A. 3D ‘On-Top’ Cell culture method. A
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latter form apparent upon apoptosis. Neither AKT or MAPK inhibition
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